More than 35,000 men in the United States die from prostate cancer each year. Now, a new study reveals the immune cell ...

Pfizer (PFE) is trading at $26.59 with shares up 9.31% year-to-date, while Guggenheim raised its price target to $36 with a Buy rating versus Wall Street’s cautious $28.14 consensus. Pfizer’s oncology ...

GLP-1 users are buying chocolate at a higher rate than the rest of the U.S., according to Swiss chocolatier Lindt & Sprüngli. The chocolate maker released data that shows the surge in weight-loss ...

Two Premium Bonds holders will have a spring in their step after winning the top £1 million prize in NS&I’s March draw. The first lucky jackpot winner is from Liverpool, holding a winning bond number ...

Bacillus Calmette-Guérin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naïve Non–Muscle-Invasive Bladder Cancer Progress or Overreach? The classification of patients with prostate cancer, based ...

Amazfit Active 3 Premium has been introduced at $169.99 (roughly Rs. 15,500). It features a 1.32-inch AMOLED display with 3,000 nits of brightness and sapphire protection, along with 4GB of storage.

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s most advanced immuno-oncology asset, the prostate cancer candidate VIR-5500, through a collaboration that could ...

If the lack of background play or downloadable offline content was one of the reasons you were holding off on subscribing to YouTube's most affordable paid subscription plan, then YouTube has some ...

This week, cancer researchers in New York are one step closer to answering a question that has plagued medical and environmental advocates for decades: What is the role of plastic exposure in the ...

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. Under the leadership of ...

Gold prices have been on a remarkable run over the past year, with the price of the precious metal consistently surpassing prior records and just recently climbing to historic levels above $5,000 per ...

Novant Health approved SUREcore and coreCARE after value analysis identified recurrent prostate core fragmentation and processing gaps that can impair complete sectioning and diagnostic confidence.